Background
==========

Increased storage of lipids in renal tubular epithelial cells (TECs) or glomerular mesangial cells contributes to kidney injury, kidney dysfunction, and tubulointerstitial fibrosis through the process of lipotoxicity \[[@b1-medscimonit-25-7702]\]. Lipotoxicity is a metabolic syndrome that arises from the accumulation of lipid intermediates \[[@b2-medscimonit-25-7702],[@b3-medscimonit-25-7702]\], and is believed to have a role in chronic kidney disease (CKD) \[[@b4-medscimonit-25-7702]\]. Thus, a better understanding of lipid metabolism at a molecular level and exploring lipid-lowering agents might represent therapeutic strategy to block lipotoxicity and protect human renal functions.

Berberine (BBR), an alkaloid extracted from*Coptis chinensis*, has a significant effect of decreasing blood lipid, including cholesterol, triglycerides, and low-density lipoprotein-cholesterol \[[@b5-medscimonit-25-7702]\], and has been involved in clinical therapy of abnormal lipid metabolism-associated CKDs, including diabetic nephropathy \[[@b6-medscimonit-25-7702]\]. Some studies have demonstrated that BBR ameliorates renal lipid accumulation, probably through accelerating fatty acid oxidation (FAO) \[[@b7-medscimonit-25-7702]\]. However, lipid-lowering mechanisms of BBR have not been completely understood.

Peroxisome proliferator-activated receptor a (PPAR-a), an FAO-regulating protein, is a central regulator in fatty acid metabolism. Deficiency in PPAR-a contributes to overloading lipid-associated tubular injury, while agonist of PPAR-a leads to the opposite \[[@b8-medscimonit-25-7702]\]. Evidence suggests that BBR promotes PPAR-a, and subsequently influences FAO in palmitate-injured TECs \[[@b7-medscimonit-25-7702]\]. However, whether and how PPAR-a involved in renal protective effect of BBR in TECs remained largely unknown. In the present study, palmitic acid (PA)-induced lipotoxicity in HK-2 cells were established, and then lipotoxicity was assessed by determining endoplasmic reticulum (ER) stress, lipid accumulation, the release of inflammatory cytokines, and the apoptosis of HK-2 cells. BBR, GW6471 (PPAR-a inhibitor) and fenofibrate (PPAR-a agonist) were used for treatment. Our results demonstrated a promising strategy targeting PPAR-a to treating lipotoxicity in TECs.

Material and Methods
====================

Cell culture and treatment
--------------------------

Culture medium for HK-2 cells (ATCC, Manassas, VA, USA) was Dulbecco's Modified Eagle Medium (DMEM)/F12 (SH30023.01B, Hyclone) with 10% fetal bovine serum (FBS; 16000-044, Gibco, USA) and 100 U/mL penicillin (Solarbio, Beijing, China) added. Under 5% CO~2~ at 37°C, HK-2 cells grew to 80% confluency, seeded in a 96-plated well (4×10^3^ cells/well in 100 μL of cultured medium), and then continued to be cultured for 12 hour.

To study the involvement of PPAR-a in the anti-lipotoxicity effect of BBR on HK-2 cells induced by PA, HK-2 cells, stimulated with 0.1 mM of PA (P5585-10G, Sigma), were treated with BBR, BBR+5 μM of PPAR-a inhibitor GW6471 (G5045-5MG, Sigma), or 10 μM of PPAR-a agonist fenofibrate (F6020-5G, Sigma). BBR, fenofibrate, and GW6471 were added to culture medium of HK-2 cells as a solution in dimethyl sulfoxide (DMSO) with final dosage of DMSO in culture medium (v/v) of 0.1%, 0.01%, and 0.05%.

Cell proliferation analysis
---------------------------

To confirm the concentration of BBR used, cells were treated with BBR (B139120, Aladdin) at a dose of 0, 1, 5, 10, 50, and 100 μM, and then proliferation at 24 hours was assessed using Cell Counting Kit-8 (CCK-8) (CP002, SAB), according to the manufacturer's instructions.

Flow cytometry analysis
-----------------------

After treatment, the apoptotic rate in the Control, PA, PA+BBR, PA+BBR+PPAR-a inhibitor and PA+PPAR-a agonist groups was determined, using Annexin V-FITC apoptosis detection kit (C1062, Beyotime, Shanghai, China). Briefly, cells in darkness were maintained with Annexin V-FITC (5 μL) followed by propidium iodide (PI) for 15 minutes, respectively. Flow cytometry (BD Biosciences, USA) was used for analysis, and apoptotic HK-2 cells (Annexin V^+^/PI^−^) were seen in the lower right quadrant.

Enzyme-linked immunosorbent assay (ELISA) assay
-----------------------------------------------

Enzyme-linked immunosorbent assay (ELISA) was conducted to assess interleukin (IL)-6 and tumor necrosis factor (TNF)-a in cultured supernatants, using 96T human IL-6 ELISA kit (Catalog Number XY-E10140) and 96T human TNF-a ELISA kit (Catalog Number XY-E10110), respectively, according to the supplier's protocols (X-Y Biotechnology Co., Ltd., Hangzhou, China).

Both human IL-6 ELISA kit and TNF-a ELISA kit had high sensitivity (ranged 0.8 to 20 ng/L and 20 to 400 ng/L, respectively) and excellent specificity for detection of human IL6 or TNF-a with no significant cross-reactivity or interference being observed.

Western blot analysis
---------------------

Bicinchoninic acid (BCA) protein assay kit (Thermo, Shanghai, China) was adopted to quantify total protein, and 50 μg of which was separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Electrophoretic pure including PPAR-a, fatty acid synthase (FAS), acetyl-CoA carboxylase polyclonal (ACC), lipoprotein lipase (LPL), carnitine palmitoyl transferase 1 (CPT1), cleaved-caspase-3, prospective evaluation of radial keratotomy (PERK), C/EBP-homologous protein (CHOP), 78 kDa glucose-regulated protein (GRP78), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were transferred to nitrocellulose membranes (Millipore, USA), and then incubated with antibody against PPAR-a (ab24509, Abcam, dilution 1: 1000), anti-FAK antibody (ab128856, Abcam, dilution 1: 1000), anti-ACC antibody (PA5-17564, Invitrogen, dilution 1: 1000), anti-LPL antibody (ab21356, Abcam, dilution 1: 1000), anti-CPT1 antibody (Ab107425, Abcam, dilution 1: 100), antibody against cleaved-caspase-3 (Ab32351, Abcam, dilution 1: 5000), anti-PERK antibody (PA5-15305, Invitrogen, dilution 1: 1000), anti-GRP78 antibody (Ab22410, Abcam, dilution 1: 1000), antibody against CHOP (Ab11419, Abcam, dilution 1: 2000) and anti-GAPDH antibody (\#5174, CST, dilution 1: 2000) at 4°C overnight followed by secondary antibodies (A0208 and A0216, Beyotime, dilution 1: 1000) for 1 hour at 25°C. Primary antibodies were diluted in blocking solution (5% nonfat milk) and secondary antibodies were diluted in Tris-buffered saline with Tween 20 (TBST solution, pH=8.0) prior to use. Immunoreactive bands of PPAR-a, FAS, ACC, LPL, CPT1, PERK, GRP78, CHOP, and GAPDH were qualified and quantitated by electrochemiluminescent (ECL) system (GE Healthcare/Amersham Biosciences) with ImageJ software (NIH, Bethesda, USA).

Real-time polymerase chain reaction (RT-PCR)
--------------------------------------------

Total RNA within HK-2 cells in Control, PA, PA+BBR, PA+BBR+PPAR-a inhibitor and PA+PPAR-a agonist groups was acquired using TRIzol regent (Invitrogen), and reverse transcribed using cDNA synthesis kit (Fermentas). The mRNA levels of PPAR-a, FAS, ACC, LPL, CPT1, PERK, GRP78, CHOP, and GAPDH were quantitative analysis by real-time polymerase chain reaction (RT-PCR) using SYBR Green PCR Kit (Thermo) with ABI Prism 7300 SDS Software (Applied Biosystem, Foster City, CA, USA). The primer sequences are presented in [Table 1](#t1-medscimonit-25-7702){ref-type="table"}.

Statistics and data analysis
----------------------------

Data was showed as mean ± standard error of the mean (SEM), calculated from 3 parallel results in each experiment. Comparison between Control and PA groups, PA and PA+BBR groups, PA and PA+PPAR-a agonist groups as well as PA+BBR and PA+BBR +PPAR-a inhibitor groups was conducted using one-way ANOVA with post-hoc Tukey test, and *P*\<0.05 was considered to be of statistical significance.

Results
=======

BBR attenuated PA-induced endoplasmic reticulum (ER) stress in HK-2 cells via upregulating PPAR-a
-------------------------------------------------------------------------------------------------

In 2011, Gao et al. investigated the protective effect of BBR on PA-induced lipotoxicity in HIT-T15 cells with the dose of 0 to 100 μM \[[@b9-medscimonit-25-7702]\]. In our present study, HK-2 cells were treated with vehicle (DMSO) or BBR (1, 5, 10, 50, and 100 μM) ([Figure 1A](#f1-medscimonit-25-7702){ref-type="fig"}). Then 24 hours later, proliferation at 24 hours was assessed using CCK-8 method. Our data suggested that BBR dose-dependently repressed HK-2 cell proliferation, thus, we chose 100 μM of BBR for the following study. After treatment for 24 hours, expression of PPAR-a was assessed in the Control, PA, PA+BBR, PA+BBR+PPAR-a inhibitor, or PA+PPAR-a agonist groups. [Figure 1B and 1C](#f1-medscimonit-25-7702){ref-type="fig"} showed that expression level of PPAR-a was significantly reduced by PA, confirming the involvement of PPAR-a in PA-induced lipotoxicity in HK-2 cells. Interestingly, both BBR and PPAR-a agonist significantly enhanced PPAR-a in PA-injured HK-2 cells. However, BBR-induced enhancement of PPAR-a in PA-injured HK-2 cells was significantly reversed by additional treatment of PPAR-a inhibitor.

Endoplasmic reticulum (ER) stress was magnified on PA-induced hepatocyte lipotoxicity \[[@b10-medscimonit-25-7702]\]. [Figure 1B and 1C](#f1-medscimonit-25-7702){ref-type="fig"} showed that expression levels of PERK, GRP78, and CHOP (3 ER stress hallmarks) were increased by PA while suppressed following BBR or PPAR-a agonist treatment, indicating that BBR and PPAR-a agonist ameliorated PA-induced ER stress in HK-2 cells. However, BBR-induced the enhancement of ER stress in PA-injured HK-2 cells were significantly reversed by additional treatment of PPAR-a inhibitor, substantiating that upregulating PPAR-a was the underlying mechanism, whereby BBR exerted inhibitory effect on PA-induced ER stress in HK-2 cells.

BBR decreased PA-induced lipid accumulation in HK-2 cells via upregulating PPAR-a
---------------------------------------------------------------------------------

After treatment for 24 hours, expression levels of genes responsible for lipogenesis, including FAS, ACC, and LPL as well as gene related to lipolysis, including CPT1 were assessed \[[@b11-medscimonit-25-7702]\]. [Figure 2A and 2B](#f2-medscimonit-25-7702){ref-type="fig"} showed that PA increased FAS, ACC and LPL while decreased CPT1, suggesting a severe lipid accumulation in HK-2 cells. PA-induced the changed expression of FAS, ACC, LPL, and CPT1 were significantly reversed by BBR or PPAR-a agonist. However, FAS, ACC, and LPL were significantly enhanced while CPT1 was reduced in PA+BBR+PPAR-a inhibitor group when compared with PA+BBR (all *P*\<0.01), substantiating that upregulating PPAR-a was the underlying mechanism, whereby BBR exerted inhibitory effect on PA-induced lipid accumulation in HK-2 cells.

BBR ameliorated PA-induced inflammation in HK-2 cells via upregulating PPAR-a
-----------------------------------------------------------------------------

After treatment for 24 hours, concentrations of inflammatory cytokine IL-6 and TNF-a in cell cultured supernatant were assessed. [Figure 3](#f3-medscimonit-25-7702){ref-type="fig"} shows that PA increased IL-6 and TNF-a, suggesting a severe inflammation. Interestingly, the release of IL-6 and TNF-a in PA-injured HK-2 cells was significantly suppressed by both BBR and PPAR-a agonist. However, BBR-induced those changes in PA-injured HK-2 cells were significantly reversed by additional treatment of PPAR-a inhibitor, substantiating that upregulating PPAR-a was the underlying mechanism, whereby BBR exerted inhibitory effect on PA-induced inflammation in HK-2 cells.

BBR ameliorated PA-induced apoptosis in HK-2 cells via upregulating PPAR-a
--------------------------------------------------------------------------

After treatment for 24 hours, cell apoptosis and expression of cleaved-caspase-3 were determined. The apoptotic rate was significant enhanced in the PA group (22.00±0.46%) when compared with the Control group (4.23±0.57%), demonstrating severe apoptosis in HK-2 cells induced by PA ([Figure 4](#f4-medscimonit-25-7702){ref-type="fig"}). BBR and PPAR-a agonist dropped the apoptotic rate to 9.53±0.42% and 16.7±1.15%, respectively, when compared to the PA group (22.00±0.46%). However, the promoted effect of BBR on apoptosis in the PA group were significantly reversed by additional treatment of PPAR-a inhibitor, substantiating that upregulating PPAR-a was the underlying mechanism, whereby BBR exerted inhibitory effect on PA-induced apoptosis in HK-2 cells. Furthermore, similar change treads of cleaved-caspase-3 expression was also observed in control, PA, PA+BBR, PA+BBR+PPAR-a inhibitor and PA+PPAR-a agonist groups, suggesting that BBR acted on PPAR-a to regulate the apoptosis of PA-injured HK-2 cells at a molecular level.

Discussion
==========

Enhanced ER stress in TECs appears to be a consequence of lipid accumulation, and ultimately leads to cells apoptosis \[[@b12-medscimonit-25-7702]\]. Furthermore, TECs display lipid accumulation frequently accompanied with the release of inflammatory cytokines, which exacerbates ER stress and accelerates tubulointerstitial fibrosis \[[@b13-medscimonit-25-7702]--[@b15-medscimonit-25-7702]\]. In this study, our data confirmed that PA significantly: 1) enhanced ER stress through increasing PERK, GRP78, and CHOP; 2) increased intracellular lipid accumulation as evidenced by obviously upregulating FAS, ACC, and LPL (lipogenesis genes) while downregulating CPTI (a lipolysis gene); 3) contributed to inflammation by promoting the release of IL-6 and TNF-a; and 4) promoted cell apoptosis and protein expression of cleaved-caspase-3, suggesting a severe lipotoxicity induced by PA in HK-2 cells.

Evidence suggests that BBR inhibits PA-induced lipid accumulation and apoptosis in TECs \[[@b7-medscimonit-25-7702]\], which was confirmed in our present study ([Figures 2](#f2-medscimonit-25-7702){ref-type="fig"}, [4](#f4-medscimonit-25-7702){ref-type="fig"}). Prolonged ER stress leads to increased apoptosis of TECs \[[@b16-medscimonit-25-7702]\]. BBR suppresses ER stress, and thereby retards hypoxia/reoxygenation (H/R)-induced apoptosis of HK-2 cells \[[@b16-medscimonit-25-7702]\]. Furthermore, elimination of ER stress ameliorates the production of pro-inflammatory cytokines in palmitate-induced lipotoxicity in cardiomyocytes \[[@b17-medscimonit-25-7702]\]. Our data first suggested the inhibitory effect of BBR on ER stress and the release of pro-inflammatory cytokines in PA-injured HK-2 cells, implicating the possible involvement of ER stress pathway in protective effect of BBR on lipotoxicity-associated apoptosis and inflammation in TECs.

PPAR-a functioned in renal lipotoxicity, and PPAR-a agonist has become more and more popular as a potential agent for protecting renal function, likely through reducing lipid deposition, retarding inflammation, and fibrosis, as well as ameliorating renal apoptosis \[[@b18-medscimonit-25-7702],[@b19-medscimonit-25-7702]\]. BBR has been shown to significantly enhance PPAR-a in PA-induced lipotoxicity in HK-2 cells \[[@b7-medscimonit-25-7702]\], thus, we further investigated whether PPAR-a was the underlying mechanism. Similar to BBR, PPAR-a agonist (fenofibrate) increased the expression of PPAR-a, downregulated lipid accumulation, inflammation, and apoptosis, yet, exerted inhibitory effect on ER stress, substantiating the inhibitory effect of PPAR-a on lipotoxicity in HK-2 cells induced by PA. However, BBR induced the enhancement of PPAR-a expression, and the changes in the events associated with lipotoxicity were significantly reversed by additional treatment with PPAR-a inhibitor (GW6471), suggesting that the PPAR-a pathway was the mechanism by which BBR showed inhibitory effect on PA-induced lipotoxicity in HK-2 cells.

Concluisons
===========

In summation, our data confirmed the inhibitory effect of BBR on PA-induced lipotoxicity in HK-2 cells through restricting ER stress, reducing lipid accumulation, alleviating the release of inflammatory factors, as well as attenuating apoptosis; and the mechanism was associated with the upregulation of PPAR-a. Moreover, targeting PPAR-a could provide a new possibility to ameliorate renal lipotoxicity and protect renal function in the further.
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![BBR ameliorated PA-induced ER stress in HK-2 cells via PPAR-a pathway. (**A**) Cell proliferation was assessed after 24 hours of BBR exposure (0, 1, 5, 10, 50, and 100 μM), using method CCK-8. HK-2 cells, stimulated with PA (0.1 mM), were treated with 100 μM of BBR, BBR+10 μM of PPAR-a inhibitor (GW6471), and 5 μM of PPAR-a agonist (fenofibrate), respectively. After treatment at 24 hours: (**B**) mRNA and (**C**) protein levels of PERK, CHOP, PPAR-a, and GRP78 were assessed by RT-PCR and western blot, respectively. \*\* *P*\<0.01 versus Control; ^\#\#^ *P*\<0.01 versus PA; ^++^ *P*\<0.01 versus PA+BBR. BBR -- berberine; PA -- palmitic acid; ER -- endoplasmic reticulum; PPAR -- peroxisome proliferator-activated receptor a; CCK-8 -- Cell Counting Kit-8; PERK -- prospective evaluation of radial keratotomy; CHOP -- C/EBP-homologous protein; GRP78 -- 78 kDa glucose-regulated protein; RT-PCR -- real-time polymerase chain reaction.](medscimonit-25-7702-g001){#f1-medscimonit-25-7702}

![BBR ameliorated PA-induced lipid accumulation in HK-2 cells via PPAR-a pathway. (**A**) mRNA and (**B**) protein levels of FAS, ACC, LPL, and CPT1 were assessed. \*\* *P*\<0.01 versus Control; ^\#\#^ *P*\<0.01 versus PA; ++ *P*\<0.01 versus PA+BBR. BBR -- berberine; PA -- palmitic acid; PPAR -- peroxisome proliferator-activated receptor a; FAS -- fatty acid synthase; ACC -- acetyl-CoA carboxylase; LPL -- lipoprotein lipase; CPT1 -- carnitine palmitoyl transferase 1.](medscimonit-25-7702-g002){#f2-medscimonit-25-7702}

![BBR ameliorated PA-induced inflammation in HK-2 cells via PPAR-a pathway. After treatment at 24 hours, levels of IL-6 and TNF-a were assessed by ELISA. \*\* *P*\<0.01 versus Control; ^\#\#^ *P*\<0.01 versus PA; ^++^ *P*\<0.01 versus PA+BBR. BBR -- berberine; PA -- palmitic acid; PPAR -- peroxisome proliferator-activated receptor a; IL -- interleukin; TNF -- tumor necrosis factor; ELISA -- enzyme-linked immunosorbent assay.](medscimonit-25-7702-g003){#f3-medscimonit-25-7702}

![BBR ameliorated PA-induced apoptosis in HK-2 cells via PPAR-a pathway. (**A**) Cell apoptosis assessed using flow cytometry; (**B**) protein levels of cleaved-caspase-3. \*\* *P*\<0.01 versus Control; ^\#\#^ *P*\<0.01 versus PA; ^++^ *P*\<0.01 versus PA+BBR. BBR -- berberine; PA -- palmitic acid; PPAR -- peroxisome proliferator-activated receptor a.](medscimonit-25-7702-g004){#f4-medscimonit-25-7702}

###### 

Primers used in real-time polymerase chain reaction analysis.

  Name                                       GenBank                                  Primer (5′-3′)
  ------------------------------------------ ---------------------------------------- ----------------------------------
  PPAR-α                                     NM_001001928.3, at 1687--1872 position   Forward: CTGAAGCTGACAGCACTAC;
  Reverse: TGAGATTAGCCACCTACCC; 186 bps                                               
                                                                                      
  FAS                                        NM_000043.5, at 3138--3286 position      Forward: TTCCCTCCTGTGTTATGG;
  Reverse: ACTTGCCCTACTTCTGTC; 149 bps                                                
                                                                                      
  ACC                                        NM_198834.2, at 9573--9677 position      Forward: CTTCAGAGGCAGGGTGGGTTAC;
  Reverse: GGGAGGAGGCATTACAGGGTTC; 104 bps                                            
                                                                                      
  LPL                                        NM_000237.2, at 1178--1299 position      Forward: CGCTCCATTCATCTCTTCATC;
  Reverse: CAGCGGTTCTTTCTACAACTC; 122 bps                                             
                                                                                      
  CPT1                                       NM_001031847.2, at 1166--1414 position   Forward: GCACATCGTCGTGTACCATC;
  Reverse: GCTGCTTTCTCCACAGCATC; 249 bps                                              
                                                                                      
  PERK                                       NM_001313915.1, at 291--535 position     Forward: TCATCCAGCCTTAGCAAAC;
  Reverse: CCCAGAGCTGAACAGATATAC; 245 bps                                             
                                                                                      
  GRP78                                      NM_005347.4, at 450--584 position        Forward: GTCCTATGTCGCCTTCACTC;
  Reverse: ACAGACGGGTCATTCCAC; 135 bps                                                
                                                                                      
  CHOP                                       NM_001195053.1, at 640--830 position     Forward: AACCAGGAAACGGAAACAG;
  Reverse: TCACCATTCGGTCAATCAG; 191 bps                                               
                                                                                      
  GAPDH                                      NM_001256799.1, at 436--653 position     Forward: AATCCCATCACCATCTTC;
  Reverse: AGGCTGTTGTCATACTTC; 218 bps                                                

RT-PCR -- real-time polymerase chain reaction; PPAR -- peroxisome proliferator-activated receptor a; FAS -- fatty acid synthase; ACC -- acetyl-CoA carboxylase; LPL -- lipoprotein lipase; CPT1 -- carnitine palmitoyl transferase 1; PERK -- prospective evaluation of radial keratotomy; GRP78 -- 78 kDa glucose-regulated protein; CHOP -- C/EBP-homologous protein; GAPDH -- glyceraldehyde-3-phosphate dehydrogenase.
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